Ahmad Bilal
- Repare Therapeutics plans to prioritize its clinical-stage oncology drug candidates, which will result in the reduction of around 25% of its workforce.
- The company said it will focus on developing its drug candidates lunresertib, camonsertib, RP-1664 and RP-3467, while reducing the size of its preclinical research and discovery operations. Most of the layoffs are expected to occur in the preclinical division, according to a statement.
- Repare expects to incur cash payments of around $1.5M to $2M in Q3 related to the workforce reductions, which are expected to generate approximately $15M in annual savings and extend its cash runway into the latter half of 2026.
